Phase II trial of combination therapy with metronomic capecitabine (C) and fulvestrant (F) in the treatment of hormone receptor-positive metastatic breast cancer (HR plus MBC)

被引：0
|
作者：
Blakely, L. J.
Schwartzberg, L. S.
Wang, G.
Somer, B. G.
Wheeler, B. M.
Stepanski, E. J.
Walker, M.
Johns, A.
机构：
[1] West Clin, Memphis, TN USA
[2] Adv Med Specialties, Miami, FL USA
[3] ACORN Res, Memphis, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11087
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Schwartzberg, Lee S.
    Wang, Grace
    Somer, Bradley G.
    Blakely, L. Johnetta
    Wheeler, Benton M.
    Walker, Mark S.
    Stepanski, Edward J.
    Houts, Arthur C.
    CLINICAL BREAST CANCER, 2014, 14 (01) : 13 - 19
  • [2] A phase II study of pembrolizumab in combination with palliative radiotherapy (RT) for hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Barroso-Sousa, Romualdo
    Krop, Ian E.
    Trippa, Lorenzo
    Tan-Wasielewski, Zhenying
    Li, Tianyu
    Osmani, Wafa
    Andrews, Chelsea
    Dillon, Deborah
    Richardson, Edward T.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Schoenfeld, Jonathan Daniel
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Fulvestrant (F) plus sorafenib (S) as salvage therapy for hormone receptor positive (HR plus ) metastatic breast cancer (MBC) failing prior aromatase inhibitor (AI) treatment.
    Lethert, Kristine H.
    Nauman, Deirdre J.
    Prado, Yolanda
    Seligman, Mark
    Karamlou, Kasra
    Ey, Frederick S.
    Chui, Stephen Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] Combination of metronomic capecitabine and letrozole in metastatic hormone receptor positive, HER2 negative breast cancer: a randomized phase II trial
    Azim, Hamdy A.
    Saleh, Mariam A.
    Eldin, Passant Essam
    Abdelhafeez, Ahmed A. M.
    Hassan, Mohamed
    Kassem, Loay
    JOURNAL OF CHEMOTHERAPY, 2025, 37 (02) : 159 - 167
  • [5] Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR plus ) metastatic breast cancer (MBC) with prior chemotherapy for advanced disease (TBCRC 035) A phase II study with pharmacodynamics markers
    Rugo, H. S.
    Mayer, E. L.
    Storniolo, A. M.
    Isaacs, C.
    Mayer, I.
    Stearns, V.
    Nanda, R.
    Nangia, J.
    Wabl, C.
    Deluca, A.
    Kochupurakkal, B.
    Wolff, A. C.
    Shapiro, G. I.
    CANCER RESEARCH, 2019, 79 (04)
  • [6] Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Tolaney, Sara M.
    Barroso-Sousa, Romualdo
    Keenan, Tanya
    Trippa, Lorenzo
    Hu, Jiani
    Luis, Ines Maria Vaz Duarte
    Wulf, Gerburg M.
    Spring, Laura
    Sinclair, Natalie Faye
    Andrews, Chelsea
    Pittenger, Jessica Demeo
    Richardson, Edward T.
    Dillon, Deborah
    Lin, Nancy U.
    Overmoyer, Beth
    Partridge, Ann H.
    VanAllen, Eliezer
    Mittendorf, Elizabeth A.
    Winer, Eric P.
    Krop, Ian E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Fulvestrant in management of hormone receptor-positive metastatic breast cancer
    Shafaee, Maryam Nemati
    Ellis, Matthew James
    FUTURE ONCOLOGY, 2018, 14 (18) : 1789 - 1800
  • [8] Treatment of HER2-positive (HER2+) hormone-receptor positive (HR plus ) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant
    Escriva-De-Romani, Santiago
    Alba, Emilio
    Rodriguez-Lescure, Alvaro
    Hurvitz, Sara
    Cejalvo, Juan Miguel
    Gion, Maria
    Ferrario, Cristiano
    Borrego, Manuel Ruiz
    Pezo, Rossanna C.
    Hamilton, Erika
    Webster, Marc
    Pluard, Timothy
    Beeram, Muralidhar
    Rodriguez, Begona Jimenez
    Linden, Hannah
    Saura, Cristina
    Omidpanah, Adam
    Harvey, Phoebe
    Savard, Marie-France
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial
    Wang, S.
    Hong, R.
    Xu, F.
    Xia, W.
    Teng, Y.
    Ouyang, Q.
    Yuan, Z.
    Jiang, K.
    Lin, Y.
    Liu, X.
    Chen, Q.
    Wu, X.
    Shi, Y.
    Huang, J.
    An, X.
    Xue, C.
    Bi, X.
    Zheng, Q.
    Chen, M.
    Li, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S374 - S374
  • [10] Efficacy of palbociclib plus fulvestrant after everolimus in hormone receptor-positive metastatic breast cancer
    Pauline du Rusquec
    Clément Palpacuer
    Loic Campion
    Anne Patsouris
    Paule Augereau
    Carole Gourmelon
    Marie Robert
    Laurence Dumas
    Folliard Caroline
    Mario Campone
    Jean-Sébastien Frenel
    Breast Cancer Research and Treatment, 2018, 168 : 559 - 566
12345